Table 6.

Multivariate analysis of prognostic factors for patients with locoregionally advanced NPC

Variable	OS		LRRFS		DMFS		DFS
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Gender (males vs. females)	0.63 (0.32–1.26)	0.191	1.25 (0.55–2.85)	0.588	0.50 (0.22–1.11)	0.087	0.71 (0.39–1.30)	0.265
Age (<50 vs. ≥50 years)	1.92 (1.17–3.15)	0.010	1.31 (0.62–2.77)	0.486	1.59 (0.93–2.72)	0.092	1.70 (1.08–2.67)	0.022
WHO histology (Type II vs. Type III)	1.87 (0.67–5.21)	0.229	1.54 (0.36–6.50)	0.561	1.59 (0.57–4.44)	0.379	1.22 (0.77–1.92)	0.433
T stage (T1–2 vs. T3–4)	1.39 (0.52–3.67)	0.512	5.69 (071–45.81)	0.102	1.00 (0.39–2.59)	0.999	1.36 (0.58–3.19)	0.475
N stage (N0–1 vs. N2–3)	1.36 (0.79–2.37)	0.270	1.13 (0.51–2.47)	0.768	1.59 (0.88–2.87)	0.126	1.29 (0.78–2.13)	0.322
Overall stage (III vs. IV)	2.50 (1.47–4.26)	0.001	1.05 (0.51–2.17)	0.897	2.54 (1.41–4.58)	0.002	1.80 (1.12–2.89)	0.016
Treatment (NAC + IMRT vs. CCRT + AC)	1.23 (0.74–2.03)	0.426	1.34 (0.65–2.77)	0.436	1.35 (0.78–2.32)	0.281	1.40 (0.60–3.25)	0.397